Skip to main content

Table 2 Results of planned meta-analyses with random effects

From: GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs

Outcome Trials (n) Estimate (HR) 95% CI P value of HR I2 (%) P value of I2
MACE
 All 8 0.86 0.79–0.94 0.006 50.0 0.080
 Prior CVD 6 0.84 0.79–0.90 < 0.001 6.1 0.370
 No prior CVD 6 0.94 0.83–1.06 0.330 0.0 0.420
CV mortality 8 0.87 0.78–0.96 0.016 18.7 0.330
Non-fatal MI 8 0.91 0.81–1.01 0.078 34.6 0.170
Non-fatal stroke 8 0.84 0.76–0.94 0.007 0.0 0.580
Heart failure 8 0.90 0.83–0.98 0.023 0.0 0.670
All-cause mortality 8 0.88 0.80–0.96 0.012 26.3 0.350
Renal endpoints 6 0.83 0.73–0.94 < 0.012 36.5 0.280
New macro 6 0.74 0.67–0.82 < 0.001 11.0 0.370
  1. Macro macroalbuminuria